Back | Next |
home / stock / apls / apls message board
Subject | By | Source | When |
---|---|---|---|
Thoughts on where this is headed? | IPO$ | investorshub | 04/13/2023 12:28:59 PM |
Anyone hear anything lately? Want to see this one go | ClayTrader | investorshub | 04/13/2023 2:05:13 AM |
$APLS The now | conix | investorshub | 04/13/2023 12:13:02 AM |
Price now up | ComptonBrosInc | investorshub | 04/12/2023 6:07:56 PM |
short squeeze article | IPO$ | investorshub | 04/12/2023 3:26:11 AM |
Time for a bounce? | conix | investorshub | 04/12/2023 3:18:49 AM |
When is this gonna take off? | IPO$ | investorshub | 04/11/2023 8:57:30 PM |
we got news | IPO$ | investorshub | 04/11/2023 6:09:49 PM |
$APLS are we finally gonna see some action | ComptonBrosInc | investorshub | 04/10/2023 10:43:03 AM |
The now up | IPO$ | investorshub | 04/10/2023 10:34:20 AM |
just the news we needed | wantprofits | investorshub | 04/09/2023 11:34:13 PM |
$APLS The now last trade up | IPO$ | investorshub | 04/09/2023 9:44:24 PM |
$APLS and the shorts continue | ClayTrader | investorshub | 04/09/2023 7:42:12 PM |
we got news | ClayTrader | investorshub | 04/09/2023 10:00:42 AM |
Have a look at this | conix | investorshub | 04/08/2023 10:11:29 AM |
The trading last trade up | wantprofits | investorshub | 04/08/2023 4:19:22 AM |
what do you make of this data? | IPO$ | investorshub | 04/08/2023 2:25:25 AM |
$APLS MomentumIts trading | IPO$ | investorshub | 04/05/2023 2:43:24 PM |
Lets go go go go... Up up and away we go. | IPO$ | investorshub | 04/04/2023 2:18:47 PM |
$APLS Price now last up | IPO$ | investorshub | 04/04/2023 10:02:38 AM |
News, Short Squeeze, Breakout and More Instantly...
Apellis Pharmaceuticals Inc. Company Name:
APLS Stock Symbol:
NASDAQ Market:
Apellis received $375 million in funding at close, with ability to access an additional $100 million Majority of initial proceeds used to buy out...
Apellis received $375 million in funding at close, with ability to access an additional $100 million Majority of initial proceeds used to buy out existing SFJ Pharmaceuticals development liability Significantly improves liquidity profile by eliminating $366 million in SFJ payments...
Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) Anticipates CHMP opinion for pegcetacoplan in GA no later than J...